European Urology
European Urology is a monthly medical journal that focuses on the field of urology. Launched in 1975, it is published by Elsevier and serves as the official journal for the European Association of Urology. The current editor-in-chief is James Catto from the University of Sheffield. As per the Journal Citation Reports, the journal had an impact factor of 13.938 in 2014.
Outlet metrics
Global
#494553
United States
#451568
Health/Medicine
#3054
Articles
-
1 month ago |
europeanurology.com | Alberto Briganti |Vita-Salute San Raffaele |Jason A. Efstathiou |Ribeirão Preto
aDepartment of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy bUnit of Urology/Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy cDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA dDepartment of Radiology, Heersink School of Medicine, University of Alabama, Birmingham, AL, USA eDepartment of Radiology, Columbia...
-
1 month ago |
europeanurology.com | Juan Rivas
Saad F, Vjaters E, Shore N, et alJ Clin Oncol 2024;42:4271–81Experts’ summary:The ARANOTE trial assessed the efficacy and safety of darolutamide in combination with androgen deprivation therapy (ADT) in comparison to ADT alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC). In this double-blind, phase 3 trial, 669 patients were randomized in a 2:1 ratio.
-
1 month ago |
europeanurology.com | Juan Rivas |Jesús Sierra
Emmett L, Subramaniam S, Crumbaker M, et alLancet Oncol 2024;25:563–71Experts’ summary:The ENZA-p trial assessed the efficacy and safety of combining [177Lu]Lu-PSMA-617 with enzalutamide in comparison to enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC) and at least two risk factors for early progression. This open-label, randomized, phase 2 trial enrolled 162 patients across 15 centers in Australia.
-
2 months ago |
europeanurology.com | Matthew J. Roberts
1 Why perform pelvic lymph node dissection? Pelvic lymph node dissection (PLND) performed during radical prostatectomy (RP) has been recommended for many years by international guidelines, including previous editions of the EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines, for staging purposes and a potential oncological benefit. An extended PLND (ePLND) template detects more metastases than a standard template and so is recommended by the guidelines when PLND is deemed necessary.
-
2 months ago |
europeanurology.com | Albert Carrion |Richard Cathomas |Eva M. Compérat |Konstantinos Dimitropoulos |Jason A. Efstathiou |Rainer Fietkau | +6 more
Contact details
Address
123 Example Street
City, Country 12345
Phone
+1 (555) 123-4567
Email Patterns
Website
http://europeanurology.com/Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →